NICE recommends Zytiga (Janssen Cilag) for metastatic Prostate Cancer - 29-Jun-2012

The National Institute for Health and Clinical Excellence (NICE) has published final guidance endorsing Zytiga (abiraterone acetate) from Janssen Cilag as an NHS treatment option for patients in England and Wales with metastatic castration resistant Prostate Cancer (mCRPC), if their disease has progressed despite having received a docetaxel-containing chemotherapy regimen.

Related News

FDA approves Xofigo (Bayer HealthCare) for Prostate Cancer

CHMP recommends Xtandi (enzalutamide) as a treatment for Prostate Cancer

Firmagon (Ferring)shows lower CV risks in treatment of Prostate Cancer

MRI-guided focal laser ablation system (Visualase) shows promise in patients with Prostate Cancer

European Commission extends Zytiga(Janssen Cilag) indication in Prostate Cancer

BayerHealthCare submits Alpharadin to FDA for treatment of castration-resistant Prostate Cancer

BayerHealthCare submits Alpharadin to EMA for treatment of castration-resistant Prostate Cancer

FDA expands Zytiga (Janssen Biotech) indication in Prostate Cancer

Related Oncology Information

View all

Oncology Clinical Guidelines

Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

NICE

Prostate cancer: diagnosis and treatment

NICE
View all

Oncology Clinical Trials

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinicaltrials.gov 08 April 2013

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)

Clinicaltrials.gov 04 April 2013
View all

Oncology Medical Journal Abstracts

Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Lung Cancer 24 April 2013

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

Lung Cancer 22 April 2013
View all

Oncology Medical Apps

CCO Oncology inPractice

Free

Cancer Signs and Symptoms

Free

Related Oncology Drugs

Back to top
View all

Latest News

Takeda acquires vaccine maker Inviragen

10 May 2015

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America...

Read full article

Results positive for Afinitor (Novartis) in BOLERO-3 study in HER2 positive Breast Cancer

19 May 2013

Results of a pivotal Phase III trial in women with HER2 positive (HER2+) advanced Breast Cancer showed that Afinitor (everolimus) tablets,...

Read full article

Study of Prolia (Amgen/GSK) plus teriparatide shows significant benefits in Osteoporosis

19 May 2013

A randomised, controlled trial of postmenopausal women with Osteoporosis shows that teriparatide and Prolia (denosumab), from Amgen/GSK,...

Read full article